Fidelity SPDR Advertisement
Home > Boards > US OTC > Medical - Drugs >

Advanced Cell Technology Inc. (ACTCD)

Add ACTCD Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator locksflooring, sports guy, Kapla, LODE MAKING ME RICH, homeslice10, lasers
Search This Board:
Last Post: 9/18/2014 7:33:32 PM - Followers: 645 - Board type: Free - Posts Today: 15

Advanced Cell Technology, Inc. (ACTC)




Company Headquarters:

Advanced Cell Technology, Inc.
P.O. Box 1700
Santa Monica, CA 90406

Tel: (310) 576 0611
Fax: (310) 576 0662


Massachusetts Laboratory Facility
33 Locke Dr.
Marlborough, MA 01752
Tel: (508) 756-1212
Fax: (508) 229-2333


Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC) is a biotechnology company developing cellular therapies for the treatment of diseases that impact millions of people worldwide. The company is currently conducting the only ongoing, FDA-cleared human embryonic stem cell (hESC)-based human clinical trials. The two trials, initiated in July 2011 at UCLA's Jules Stein Eye Institute, use retinal pigment epithelial (RPE) cells derived from hESCs to treat forms of macular degeneration. ACT also recently received approval from the UK Medicines & Healthcare Products Regulatory Agency (MHRA) to conduct the first hESC trial in Europe. The company is also developing its Hemangioblast (HG) platform for the treatment of blood and cardiovascular diseases, its Phase II-cleared Myoblast stem cell therapy for the treatment of chronic heart failure and other cardiac conditions, and other programs.

ACT's principal laboratory and GMP facility is in Marlborough, Massachusetts, and its corporate offices are in Santa Monica, California. ACT is led by an experienced management team and a world-class scientific team helmed, respectively, by interim chairman and CEO Gary Rabin and chief scientific officer Robert Lanza, M.D.


ACT owns or licenses more than 150 patents and patent applications related to stem cell therapy and regenerative medicine, and is positioning itself to have a dominant patent position around its stem cell-derived RPE program in leading markets around the world.
In 2010 ACT secured three far-reaching patents related to its RPE program, and more recently was issued the first patent for generating hemangioblast cells to treat a broad spectrum of vascular and hematopoietic disorders.

The company's RPE and HG programs are hESC-based, and its Myoblast program for cardiac disease is an adult autologous stem cell therapy. As documented in NATURE and Cell Stem Cell, ACT developed the "single-cell blastomere" technique, the first-ever proven alternative method for successful hESC generation without harm to the embryo, for which it was recently issued a broad patent
RPE Program - ACT has developed a fully-differentiated RPE cell derived from human embryonic stem cells, which can be used as a cellular therapy to treat retinal degenerative diseases. In July 2011 ACT initiated two Phase I/II clinical trials to test the safety of the therapy for Stargardt's Macular Dystrophy (SMD), and for Dry Age-Related Macular Degeneration (Dry AMD). Dry AMD represents a $25-30 Billion market in the US and Europe alone, and there are no approved therapies currently available for either condition. Two patients have thus far been treated at UCLA, Institutional Review Board (IRB) approval for the SMD clinical trial has also been issued by Oregon Health & Science University (OHSU) and European regulatory clearance has been granted to initiate the first hESC trial in Europe.
Other recent milestones in ACT's RPE program include: the NIH proposed expanding its definition of hESCs for funding purposes, in part to accommodate ACT's lines derived using its patented "embryo-safe" single-cell blastomere technique; and both the FDA and the European Medicines Agency (EMA) granting ACT's RPE cells "Orphan" status for treatment of Stargardt's Disease.
Hemangioblast Program - ACT's Hemangioblast program is for the treatment of blood and cardiovascular diseases. A paper published in NATURE Methods revealed the company's successful generation of functional Hemangioblast cells from human embryonic stem cells, and a paper published earlier this year in Cell Research indicated that hESCs could be a potentially unlimited source of platelets for transfusion.
Myoblast Program - ACT's Myoblast treatment may prove particularly beneficial for patients who have experienced a serious heart attack and are at risk for heart failure. ACT has secured FDA approval to commence with Phase II clinical trials. The Myoblast program has several advantages over currently-available approaches, including symptom management and disease modification.

Dr. Lanza explains some of the technology we are pursuing:

For more information visit



Share Structure as of November 30, 2011:

Outstanding Shares

Reserved Shares

Authorized and Unreserved Shares



Authorized Preferred Shares



The following table sets forth information regarding beneficial ownership of our capital stock as of November 30, 2011 by:

·  5% or greater stockholders;
·  Each of our directors and named executive officers; and
·  All of our directors and executive officers, as a group.


Name and Address (1) of Beneficial Owner                                                                                         Common Stock Beneficially Owned                   Percentage of Shares Beneficially Owned 
5% or Greater Stockholders
Directors and Named Executive Officers
William M. Caldwell, IV**                                                                                                                             95,415,141 (1)                                                           5.58%%

Robert P. Lanza, M.D.                                                                                                                                  51,199,082 (2)                                                           2.97%%

Alan C. Shapiro                                                                                                                                           20,150,927 (3)                                                           1.18%%
Erkki Ruoslahti                                                                                                                                            2,500,000 (4)                                                                *
Gary Rabin                                                                                                                                                 23,087,430 (5)                                                           1.35%
Directors and Executive Officers as a Group (5 Persons)                                                                                192,352,580                                                               11.08%%


* Less than 1%

** Mr. Caldwell passed away on December 13, 2010

(1) Includes 5,108,546 shares subject to stock options that are currently exercisable or exercisable within 60 days of November 30, 2011.

(2) Includes 17,583,207 shares subject to stock options that are currently exercisable or exercisable within 60 days of November 30, 2011.

(3) Includes (i) 17,032,587 shares subject to convertible debentures, board fees, common stock grant held by The Shapiro Family Trust and of
which Dr. Shapiro may be deemed the beneficial owner, (ii) 3,018,340 shares subject to warrants in connection with the 2005-2008
convertible debentures, and (iii) 100,000 shares subject to stock options that are currently exercisable or exercisable within 60 days of
November 30, 2011.

(4) Includes 100,000 shares issuable upon exercise of options exercisable within 60 days of November 30, 2011. Effective August 1, 2011,
Erkki Ruoslahti resigned from the Board of Directors of the Company.

(5) Includes indirect ownership of (i) 1,239,501 shares issued to PDPI, LLC on December 22, 2010, upon exercise of certain warrants, which
such number of shares represents Mr. Rabin's proportional interest in the total number of shares held by PDPI, LLC, based on his 33.33%
equity interest in the entity. Mr. Rabin disclaims beneficial ownership in the shares held by PDPI, LLC, and (ii) 7,000,000 shares subject
to stock options that are currently exercisable or exercisable within 60 days of November 30, 2011.

There are no arrangements known to the Company, including any pledge by any person of securities of the Company, the operation of
which may at a subsequent date result in a change in control of the Company.

Media Relations

Bill Douglass
Gotham Communications, LLC
bill [at] gothamcomm [dot] com


Martina Schwarzkopf, Ph.D.
Russo Partners, LLC
(212) 845-4292
martina.schwarzkopf [at] russopartnersllc [dot] com

Investor Relations

James Young
jyoung [at] ceocast [dot] com
(212) 732-4300






All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.




Rules of the board according to IHUB:


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
ACTC News: OTC Stocks Daily Trading Focus: Windstream Technologies, Inc. Blue Earth, Inc. Creative Edge Nutrition, Inc. Brainstorm Cell ... 07/01/2014 08:00:00 AM
ACTC News: OTC Stocks Daily Trading Focus: Windstream Technologies, Inc. Blue Earth, Inc. Creative Edge Nutrition, Inc. Brainstorm Cell ... 07/01/2014 08:00:00 AM
ACTC News: Current Report Filing (8-k) 05/29/2014 05:00:40 PM
ACTC News: Quarterly Report (10-q) 05/08/2014 04:41:06 PM
ACTC News: Amended Annual Report (10-k/a) 04/29/2014 04:36:14 PM
News News Alert: Amended Statement of Changes in Beneficial Ownership (4/a) 09/18/2014 04:10:16 PM
#67180  Sticky Note $ACTC's May2014 Presentation Posted since on $ACTC website. Enjoy! lasers 06/06/14 12:22:51 AM
#73225   GEE, Where did the PARTY go? Lexxy 09/18/14 07:33:32 PM
#73224   This is for the Derivative Securities they have, mind1 09/18/14 04:23:16 PM
#73223   NewForm 4s ouot for same three people at Reetala 09/18/14 04:17:15 PM
#73222   With ACTCD's Tufts dog trial reports, it would chuckanutman 09/18/14 12:58:31 PM
#73221   Stem cells for critters. interesting reading. Shiskabill 09/18/14 12:42:35 PM
#73220   I have to agree. Wopsal101 09/18/14 11:22:12 AM
#73219   More power to them. We can always take homeslice10 09/18/14 10:18:47 AM
#73218   The 56000 shs sold could represent previous held mind1 09/18/14 08:58:58 AM
#73217   And if as I believe the exercise price Reetala 09/18/14 08:55:16 AM
#73216   56000 was one third of the shares they Wopsal101 09/18/14 08:01:46 AM
#73215   Reads they get 56000 3 times. The next homeslice10 09/18/14 06:56:39 AM
#73214   Why besides AMD and SMD? How about because Auger08 09/18/14 03:11:42 AM
#73213   Ok. It is absolutely not important. BUT ACTC SMD2014 09/18/14 12:37:56 AM
#73212   All, Please stop speculating and maybe you shall SMD2014 09/18/14 12:28:56 AM
#73211   Disingenuous Scientists Join Advanced Cell Technology's New Scientific ddls 09/18/14 12:23:01 AM
#73210   Besides AMD and SMD , medically who has Gastrodamas 09/17/14 09:10:18 PM
#73209   I'm sure they r expecting some delay and homeslice10 09/17/14 09:10:14 PM
#73208   What do you mean Auger08 09/17/14 09:01:25 PM
#73207   What has Lanza accomplished that has helped mankind? Gastrodamas 09/17/14 09:00:52 PM
#73206   Just a guess PHASE 2 will start in Gastrodamas 09/17/14 08:56:13 PM
#73205   Pure Coincidence? I've become increasingly concerned about this Hockey33 09/17/14 07:08:42 PM
#73204   Better reread that homeslice10 09/17/14 06:36:48 PM
#73203   NEJM Sept 18, 2014. No $ACTCD TLD Publication yet. lasers 09/17/14 05:25:35 PM
#73202   IMO I do not think that it is SMD2014 09/17/14 05:22:14 PM
#73201   NEJM Is my pipe dream although is seems to Booski 09/17/14 04:50:31 PM
#73200   quicker on the draw, Mind1. Reetala 09/17/14 04:08:03 PM
#73199   Hopefully whatever they buy stabilize s them for homeslice10 09/17/14 04:07:15 PM
#73198   re reference to 56,000 share transactions: Reetala 09/17/14 04:07:06 PM
#73197   56000 shs matches the form 4 from yesterday. mind1 09/17/14 04:06:35 PM
#73196   Very interesting... I wonder Auger08 09/17/14 04:01:25 PM
#73195   Someone sold 56000 shares. Interesting homeslice10 09/17/14 03:57:12 PM
#73194   Wow I take it back, it got filled. Auger08 09/17/14 03:56:31 PM
#73193   Excuse me: 50000 share order sitting on the Auger08 09/17/14 03:55:20 PM
#73192   Hope you had your glasses on or you Auger08 09/17/14 03:50:48 PM
#73191   Exactly. They can sell fewer shares and make homeslice10 09/17/14 01:17:27 PM
#73190   I know it wouldn't happen but I be Killtoy 09/17/14 12:58:31 PM
#73189   I'm fine w 7 per share heading into homeslice10 09/17/14 12:49:43 PM
#73188   I need new glasses or removal of cataracts---I north40000 09/17/14 12:19:32 PM
#73187   There is no truth to this statement. It's Auger08 09/17/14 11:40:48 AM
#73186   I'd say we can tell by lanza sales homeslice10 09/17/14 11:14:35 AM
#73185   Bob is not the only one that wants Booski 09/17/14 11:10:25 AM
#73184   There will be no delays as the latest lasers 09/17/14 11:02:35 AM
#73183   How do you know the truth of both north40000 09/17/14 10:52:50 AM
#73182   im sure we would know if it was fulleroots 09/17/14 10:48:46 AM
#73181   Insider milking is driving us back to 7 homeslice10 09/17/14 10:47:56 AM
#73180   Will publication in peer reviewed journal then be north40000 09/17/14 10:47:13 AM
#73179   is the good doctor who gets his NEJM cty 09/17/14 10:12:57 AM
#73178   Cohort 4, is the same as the other lasers 09/17/14 10:11:42 AM
#73177   How many have enrolled in cohort 4? I north40000 09/17/14 10:04:11 AM
#73176   $ACTCD is currently in RPEs Phase1/2A. $ACTCD is lasers 09/17/14 09:51:18 AM